These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 29349515)
1. Matrix metalloproteinase-2 and -9 activity levels increase in cutaneous lupus erythematosus lesions and correlate with disease severity. Ertugrul G; Keles D; Oktay G; Aktan S Arch Dermatol Res; 2018 Mar; 310(2):173-179. PubMed ID: 29349515 [TBL] [Abstract][Full Text] [Related]
2. Expression of matrix metalloproteinases and their inhibitors in experimental retinal ischemia-reperfusion injury in rats. Zhang X; Sakamoto T; Hata Y; Kubota T; Hisatomi T; Murata T; Ishibashi T; Inomata H Exp Eye Res; 2002 May; 74(5):577-84. PubMed ID: 12076079 [TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinase-9,-3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables. Işlekel H; Oktay G; Terzi C; Canda AE; Füzün M; Küpelioğlu A Cell Biochem Funct; 2007; 25(4):433-41. PubMed ID: 16615041 [TBL] [Abstract][Full Text] [Related]
4. Glomerular expression of matrix metalloproteinases in systemic lupus erythematosus in association with activity index and renal function. Adamidis KN; Kopaka ME; Petraki C; Charitaki E; Apostolou T; Christodoulidou C; Nikolopoulou N; Giatromanolaki A; Vargemesis V; Passadakis P Ren Fail; 2019 Nov; 41(1):229-237. PubMed ID: 30973283 [TBL] [Abstract][Full Text] [Related]
5. The expression of human corneal MMP-2, MMP-9, proMMP-13 and TIMP-1 in bullous keratopathy and keratoconus. Predović J; Balog T; Marotti T; Gabrić N; Bohac M; Romac I; Dekaris I Coll Antropol; 2008 Oct; 32 Suppl 2():15-9. PubMed ID: 19138000 [TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging. Baker EA; Bergin FG; Leaper DJ Br J Surg; 2000 Sep; 87(9):1215-21. PubMed ID: 10971431 [TBL] [Abstract][Full Text] [Related]
7. Increased expression of matrix metalloproteinase-2, matrix metalloproteinase-9 and matrix metalloproteinase-13 in lesional skin of bullous pemphigoid. Niimi Y; Pawankar R; Kawana S Int Arch Allergy Immunol; 2006; 139(2):104-13. PubMed ID: 16374020 [TBL] [Abstract][Full Text] [Related]
8. Gelatinase expression and activity in the synovium and skin of patients with erosive psoriatic arthritis. Hitchon CA; Danning CL; Illei GG; El-Gabalawy HS; Boumpas DT J Rheumatol; 2002 Jan; 29(1):107-17. PubMed ID: 11824946 [TBL] [Abstract][Full Text] [Related]
9. [The expression of matrix metalloproteinases and their tissue inhibitors in pleomorphic adenoma]. Chen Y; Tian K; Geng N; Yang MZ; Zhang WP Zhonghua Kou Qiang Yi Xue Za Zhi; 2005 Jan; 40(1):58-61. PubMed ID: 15774155 [TBL] [Abstract][Full Text] [Related]
10. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer. Kim TD; Song KS; Li G; Choi H; Park HD; Lim K; Hwang BD; Yoon WH BMC Cancer; 2006 Aug; 6():211. PubMed ID: 16916471 [TBL] [Abstract][Full Text] [Related]
11. Expression of matrix metalloproteinases and related tissue inhibitors in the cyst fluids of ovarian mucinous neoplasms. Furuya M; Ishikura H; Kawarada Y; Ogawa Y; Sakuragi N; Fujimoto S; Yoshiki T Gynecol Oncol; 2000 Aug; 78(2):106-12. PubMed ID: 10926788 [TBL] [Abstract][Full Text] [Related]
12. Elevated levels of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 during the acute phase of Kawasaki disease. Chua PK; Melish ME; Yu Q; Yanagihara R; Yamamoto KS; Nerurkar VR Clin Diagn Lab Immunol; 2003 Mar; 10(2):308-14. PubMed ID: 12626459 [TBL] [Abstract][Full Text] [Related]
13. Role of matrix metalloproteinases 1, 2, and 9 and tissue inhibitor of matrix metalloproteinase-1 in chronic venous insufficiency. Saito S; Trovato MJ; You R; Lal BK; Fasehun F; Padberg FT; Hobson RW; Durán WN; Pappas PJ J Vasc Surg; 2001 Nov; 34(5):930-8. PubMed ID: 11700497 [TBL] [Abstract][Full Text] [Related]
14. Comparison of interleukin-6 and matrix metalloproteinase expression in the subretinal fluid and the vitreous during proliferative vitreoretinopathy: correlations with extent, duration of RRD and PVR grade. Symeonidis C; Papakonstantinou E; Androudi S; Georgalas I; Rotsos T; Karakiulakis G; Diza E; Dimitrakos SA Cytokine; 2014 Jun; 67(2):71-6. PubMed ID: 24725542 [TBL] [Abstract][Full Text] [Related]
15. The study of Cutaneous Lupus Erythematosus Disease Area and Severity Index in Indian patients with systemic lupus erythematosus. Salphale P; Danda D; Chandrashekar L; Peter D; Jayaseeli N; George R Lupus; 2011 Dec; 20(14):1510-7. PubMed ID: 21997966 [TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease. Ulrich D; Hrynyschyn K; Pallua N Plast Reconstr Surg; 2003 Oct; 112(5):1279-86. PubMed ID: 14504511 [TBL] [Abstract][Full Text] [Related]
17. Levels of matrix metalloproteinase-2, -9 and -8 in the skin, serum and saliva of smokers and non-smokers. Raitio A; Tuomas H; Kokkonen N; Salo T; Sorsa T; Hanemaaijer R; Oikarinen A Arch Dermatol Res; 2005 Dec; 297(6):242-8. PubMed ID: 16215764 [TBL] [Abstract][Full Text] [Related]
18. Effects of Plasmodium falciparum-infected erythrocytes on matrix metalloproteinase-9 regulation in human microvascular endothelial cells. D'Alessandro S; Basilico N; Prato M Asian Pac J Trop Med; 2013 Mar; 6(3):195-9. PubMed ID: 23375032 [TBL] [Abstract][Full Text] [Related]
19. Expression of the matrix metalloproteinases MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 in systemic lupus erythematosus patients. Vira HJ; Pradhan VD; Umare VD; Chaudhary AK; Rajadhyksha AG; Nadkar MY; Ghosh K; Nadkarni AH Neth J Med; 2020 Sep; 78(5):261-268. PubMed ID: 33093251 [TBL] [Abstract][Full Text] [Related]
20. Imbalance between matrix metalloproteinases (MMP-9 and MMP-2) and tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in acute respiratory distress syndrome patients. Lanchou J; Corbel M; Tanguy M; Germain N; Boichot E; Theret N; Clement B; Lagente V; Malledant Y Crit Care Med; 2003 Feb; 31(2):536-42. PubMed ID: 12576963 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]